Qi Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qi Zhang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Ying-Ying Tan
Shaanxi Key Laboratory of Chinese Medicine Encephalopathy, Shaanxi University of Chinese Medicine, Century Avenue, Xianyang, Shaanxi, 712046, P. R. China
3 shared publications- Yongchang Diwu
Discipline Innovation Team of Shaanxi, University of Chinese Medicine, Xianyang, People’s Republic of China
3 shared publications Yonghao Wang
Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, 712046, China; Shaanxi Key Laboratory of Chinese Medicine Encephalopathy, Shaanxi University of Chinese Medicine, Xianyang, 712046, China
3 shared publications- Yuan Zhou
Department of Anatomy, Basic Medical College, Shaanxi University of Chinese Medicine, Xianyang, China
3 shared publications - Dong-Yuan Cao
Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, Xi'an Jiaotong University College of Stomatology, Xi'an, Shaanxi 710004, China; Department of Neural and Pain Sciences, School of Dentistry; the UM Center to Advance Chronic Pain Research, University of Maryland Baltimore, Baltimore, MD 21201, USA
2 shared publications Fan-Rong Yao
Department of Biochemistry and Molecular Biology, Brody School of Medicine, East Carolina University, Greenville, NC, United States
2 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 370, 122059
Gastrodin ameliorates cognitive impairment induced by a high-salt diet combined with chronic cerebral hypoperfusion by regulating cerebral blood flow and preserving BBB-related structural integrity
- 16 June 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 370, 122059
Open AccessGastrodin ameliorates cognitive impairment induced by a high-salt diet combined with chronic cerebral hypoperfusion by regulating cerebral blood flow and preserving BBB-related structural integrity
- 28 November 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 480, 125673
Insights and considerations on predicting cognitive and behavioral disturbances in MND with pure motor onset
- 28 November 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 480, 125673
Insights and considerations on predicting cognitive and behavioral disturbances in MND with pure motor onset
- Open Access
- 26 November 2025
- Published by Science Publishing Group in Clinical Neurology and Neuroscience
- Vol. 9 (4) , 52-61
Neurovascular Coupling in Neurological Disorders: A Comprehensive Review
This article provides a systematic review of current research on Neurovascular Coupling (NVC), covering its fundamental mechanisms, role in diseases, investigative technologies, and future directions. NVC describes the process where neuronal activity triggers localized changes in cerebral blood flow (CBF). This mechanism is orchestrated by the Neurovascular Unit (NVU), a functional complex comprising neurons, glial cells (e.g., astrocytes), and vascular cells (e.g., endothelial cells, pericytes, vascular smooth muscle cells). These components work in concert through intercellular signaling to co-regulate CBF. The regulation involves various vasoactive substances, including nitric oxide (NO) and prostaglandin E2 (PGE2).Dysfunction of NVC is a critical pathological mechanism in neurological disorders. In Alzheimer's disease, abnormalities across the NVU lead to blood-brain barrier disruption and impaired clearance of amyloid-β, exacerbating cognitive decline. Similarly, in cerebral small vessel disease, endothelial dysfunction manifesting as impaired NVC is a key feature, with severity correlating with structural damage like white matter hyperintensities. Following an ischemic stroke, NVU component abnormalities cause acute NVC decoupling, and the degree of functional recovery is closely associated with neurological prognosis. Technologies for studying NVC are evolving. Established methods include functional Magnetic Resonance Imaging (fMRI), which measures the blood-oxygen-level-dependent (BOLD) signal, and transcranial Doppler ultrasound. Recent advancements feature novel tools like high-speed, large-field-of-view photoacoustic/fluorescence hybrid microscopes (e.g., LiTA-HM), enabling cortex-wide imaging of neurovascular dynamics with subcellular resolution. Current research challenges include reliance on animal models. Future directions should integrate structural and functional neuroimaging techniques. Therapeutically, strategies aimed at enhancing endothelial function to restore NVC hold promise. Combining advanced imaging with omics technologies will likely deepen the understanding of the NVU and propel the field toward precise prevention and treatment of NVC-related diseases.
- 26 November 2025
- Published by Science Publishing Group in Clinical Neurology and Neuroscience
- Vol. 9 (4) , 52-61
Open AccessNeurovascular Coupling in Neurological Disorders: A Comprehensive Review
This article provides a systematic review of current research on Neurovascular Coupling (NVC), covering its fundamental mechanisms, role in diseases, investigative technologies, and future directions. NVC describes the process where neuronal activity triggers localized changes in cerebral blood flow (CBF). This mechanism is orchestrated by the Neurovascular Unit (NVU), a functional complex comprising neurons, glial cells (e.g., astrocytes), and vascular cells (e.g., endothelial cells, pericytes, vascular smooth muscle cells). These components work in concert through intercellular signaling to co-regulate CBF. The regulation involves various vasoactive substances, including nitric oxide (NO) and prostaglandin E2 (PGE2).Dysfunction of NVC is a critical pathological mechanism in neurological disorders. In Alzheimer's disease, abnormalities across the NVU lead to blood-brain barrier disruption and impaired clearance of amyloid-β, exacerbating cognitive decline. Similarly, in cerebral small vessel disease, endothelial dysfunction manifesting as impaired NVC is a key feature, with severity correlating with structural damage like white matter hyperintensities. Following an ischemic stroke, NVU component abnormalities cause acute NVC decoupling, and the degree of functional recovery is closely associated with neurological prognosis. Technologies for studying NVC are evolving. Established methods include functional Magnetic Resonance Imaging (fMRI), which measures the blood-oxygen-level-dependent (BOLD) signal, and transcranial Doppler ultrasound. Recent advancements feature novel tools like high-speed, large-field-of-view photoacoustic/fluorescence hybrid microscopes (e.g., LiTA-HM), enabling cortex-wide imaging of neurovascular dynamics with subcellular resolution. Current research challenges include reliance on animal models. Future directions should integrate structural and functional neuroimaging techniques. Therapeutically, strategies aimed at enhancing endothelial function to restore NVC hold promise. Combining advanced imaging with omics technologies will likely deepen the understanding of the NVU and propel the field toward precise prevention and treatment of NVC-related diseases.
- 26 November 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (2) , 531-545
The role of stress in the comorbidity of migraine and other chronic primary pain
Background: Chronic migraine is one of the most common causes of headache, belonging to the chronic primary pain (CPP) classification, along with fibromyalgia syndrome (FMS), temporomandibular disorders (TMD), and irritable bowel syndrome (IBS), based on the International Classification of Diseases‐11. The comorbidity between these pain disorders is commonly seen in the clinic. Stress directly and indirectly affects the pathophysiological mechanisms related to migraine and plays an important role in the co‐occurrence and development of migraine, FMS, TMD, and IBS. Methods: We systematically searched PubMed and Web of Science databases, using combined keywords: stress, migraine, comorbidity, fibromyalgia syndrome, temporomandibular disorders, irritable bowel syndrome, pathological mechanisms, animal models, and treatment strategies, while emphasizing high impact studies. Literature was screened based on relevance, scientific rigor, and evidence level, prioritizing studies on stress‐related comorbidity mechanisms, models, or treatments. Exclusion criteria included single case reports, non‐full‐text conference abstracts, non‐English articles, low‐relevance studies, low‐quality methodologies, and general opinions (except authoritative consensus/guidelines). Results: Clinical and preclinical studies support that potential stress‐related mechanisms underlie these comorbidities, including dysfunction of hypothalamic–pituitary–adrenal axis, dysregulation of autonomic nervous system, and central sensitization. We highlight the development and application of preclinical stress‐induced comorbid models as crucial tools for investigating these shared mechanisms. Stress targeted interventions have potential in managing these conditions, but mechanisms and efficacy stability remain to be clarified. Conclusion: Stress may be a key driver of migraine and CPP comorbidities. Stress induced preclinical models support mechanism exploration, and stress‐targeted therapies hold promise for improving patient prognosis. Future research should deepen mechanistic studies and optimize models/therapies to enhance clinical care.
- 26 November 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (2) , 531-545
The role of stress in the comorbidity of migraine and other chronic primary pain
Background: Chronic migraine is one of the most common causes of headache, belonging to the chronic primary pain (CPP) classification, along with fibromyalgia syndrome (FMS), temporomandibular disorders (TMD), and irritable bowel syndrome (IBS), based on the International Classification of Diseases‐11. The comorbidity between these pain disorders is commonly seen in the clinic. Stress directly and indirectly affects the pathophysiological mechanisms related to migraine and plays an important role in the co‐occurrence and development of migraine, FMS, TMD, and IBS. Methods: We systematically searched PubMed and Web of Science databases, using combined keywords: stress, migraine, comorbidity, fibromyalgia syndrome, temporomandibular disorders, irritable bowel syndrome, pathological mechanisms, animal models, and treatment strategies, while emphasizing high impact studies. Literature was screened based on relevance, scientific rigor, and evidence level, prioritizing studies on stress‐related comorbidity mechanisms, models, or treatments. Exclusion criteria included single case reports, non‐full‐text conference abstracts, non‐English articles, low‐relevance studies, low‐quality methodologies, and general opinions (except authoritative consensus/guidelines). Results: Clinical and preclinical studies support that potential stress‐related mechanisms underlie these comorbidities, including dysfunction of hypothalamic–pituitary–adrenal axis, dysregulation of autonomic nervous system, and central sensitization. We highlight the development and application of preclinical stress‐induced comorbid models as crucial tools for investigating these shared mechanisms. Stress targeted interventions have potential in managing these conditions, but mechanisms and efficacy stability remain to be clarified. Conclusion: Stress may be a key driver of migraine and CPP comorbidities. Stress induced preclinical models support mechanism exploration, and stress‐targeted therapies hold promise for improving patient prognosis. Future research should deepen mechanistic studies and optimize models/therapies to enhance clinical care.
- 18 August 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 477, 123660
Enhancing prognostic models for stroke outcomes in older patients: Insights from prestroke frailty and disability assessments
- 18 August 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 477, 123660
Enhancing prognostic models for stroke outcomes in older patients: Insights from prestroke frailty and disability assessments
- 2 June 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (3) , 1-12
Neuroprotective Effects of Tectoridin in H2O2-Induced Oxidative Stress and an Amyloid-Infused Rat Model of Alzheimer’s Disease
This study aims to examine the effects of tectoridin in both in vitro and in vivo models of Alzheimer’s disease. In vitro, oxidative stress was induced in PC12 cells using 400 µM of hydrogen peroxide (H₂O₂) to simulate cellular damage. In vivo, a rat model of Alzheimer’s disease was established through repeated intracerebroventricular administration of soluble amyloid-beta (Aβ1–42) to induce neurodegeneration. The effects of tectoridin on oxidative stress markers and protein expression levels were assessed. Tectoridin treatment significantly improved cell survival and enhanced antioxidant defense by increasing the activities of superoxide dismutase (SOD) and catalase (CAT), as well as glutathione (GSH) levels in H₂O₂-exposed PC12 cells. Polymerase chain reaction (PCR) and western blot analyses revealed that tectoridin upregulated the expression of Bcl-2 while downregulating the expression of Bax, caspase-3, and caspase-9, suggesting a reduction in apoptotic signaling. In the in vivo rat model, tectoridin mitigated Aβ1-42-induced neurodegeneration, leading to improvements in spatial learning and memory performance and reduced neurofibrillary tangles. Tectoridin treatment also improved oxidative stress parameters by increasing SOD and GSH levels while reducing malondialdehyde (MDA) content. Western blot analysis further demonstrated that tectoridin downregulated the expression of amyloid-beta (Aβ1–40), amyloid precursor protein (APP), tau, Bax, caspase-3, and caspase-9, while upregulating Bcl-2. These results suggest that tectoridin exerts neuroprotective effects by modulating oxidative-antioxidant balance and inhibiting apoptotic pathways, indicating its potential as a therapeutic agent for Alzheimer’s disease.
- 2 June 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (3) , 1-12
Neuroprotective Effects of Tectoridin in H2O2-Induced Oxidative Stress and an Amyloid-Infused Rat Model of Alzheimer’s Disease
This study aims to examine the effects of tectoridin in both in vitro and in vivo models of Alzheimer’s disease. In vitro, oxidative stress was induced in PC12 cells using 400 µM of hydrogen peroxide (H₂O₂) to simulate cellular damage. In vivo, a rat model of Alzheimer’s disease was established through repeated intracerebroventricular administration of soluble amyloid-beta (Aβ1–42) to induce neurodegeneration. The effects of tectoridin on oxidative stress markers and protein expression levels were assessed. Tectoridin treatment significantly improved cell survival and enhanced antioxidant defense by increasing the activities of superoxide dismutase (SOD) and catalase (CAT), as well as glutathione (GSH) levels in H₂O₂-exposed PC12 cells. Polymerase chain reaction (PCR) and western blot analyses revealed that tectoridin upregulated the expression of Bcl-2 while downregulating the expression of Bax, caspase-3, and caspase-9, suggesting a reduction in apoptotic signaling. In the in vivo rat model, tectoridin mitigated Aβ1-42-induced neurodegeneration, leading to improvements in spatial learning and memory performance and reduced neurofibrillary tangles. Tectoridin treatment also improved oxidative stress parameters by increasing SOD and GSH levels while reducing malondialdehyde (MDA) content. Western blot analysis further demonstrated that tectoridin downregulated the expression of amyloid-beta (Aβ1–40), amyloid precursor protein (APP), tau, Bax, caspase-3, and caspase-9, while upregulating Bcl-2. These results suggest that tectoridin exerts neuroprotective effects by modulating oxidative-antioxidant balance and inhibiting apoptotic pathways, indicating its potential as a therapeutic agent for Alzheimer’s disease.
- Open Access
- 2 February 2024
- Published by Wiley in International Journal of Hypertension
- Vol. 2024, 1-13
Da-Chuan-Xiong Decoction Ameliorates Sodium Sensitivity and Plasma Norepinephrine via Attenuation of Brain Oxidative Stress in the DOCA-Salt Hypertensive Rats
Background. Da-Chuan-Xiong Decoction (DCXD) is an aqueous extract from a classic Chinese herbal formula composed of dried rhizomes of Ligusticum chuanxiong Hort and Gastrodia elata Bl. in the mass ratio of 4:1. It has been long used to treat chronic cardiovascular disease caused by blood stasis and wind pathogen in the clinic. This experimental study aimed to investigate the blood pressure (BP)-lowering effect of DCXD treatment on hypertension and underlying mechanisms. Methods. Male SpragueDawley rats were used in the experiment, and the hypertensive models were created by administering deoxycorticosterone acetate (DOCA) in conjunction with a high salt intake in uninephrectomized rats. DCXD was administered to hypertensive rats by oral gavage daily at a dose of 5g/kg or 2.5g/kg bodyweight for 28days. The brain sodium sensitivity, ENaC function, superoxide anion level, NADPH oxidase activity, and expression of ENaC, p67phox, p47phox, and Rac1 in the paraventricular nucleus were assessed by using the appropriate methods. Results. The 28days of DCXD (5g/kg) treatment significantly reduced the increased BP effectively, inhibited the enhanced heart index, kidney index, and 24h urinary protein, and improved the progressive pathological changes of heart and kidney, which was comparable to that of the positive control amlodipine. DCXD treatment also caused a marked reduction in plasma norepinephrine and induced a significant improvement in brain sodium sensitivity and ENaC function in DOCA-salt hypertensive rats. Rats in DCXD-treated groups also exhibited decreased superoxide anion levels and NADPH oxidase activity in the paraventricular nucleus. The level of ENaC, p67phox, and Rac1 protein expression in the paraventricular nucleus was significantly downregulated by DCXD treatment in DOCA-salt hypertensive rats. Conclusions. These findings indicate that the depressor action and sympathetic inhibition of DCXD on salt-sensitive hypertension may be by ameliorating brain sodium sensitivity, modulating ENaC function, and inhibiting the expression of ENaC and NADPH oxidase in the hypothalamic paraventricular nucleus.
- 2 February 2024
- Published by Wiley in International Journal of Hypertension
- Vol. 2024, 1-13
Open AccessDa-Chuan-Xiong Decoction Ameliorates Sodium Sensitivity and Plasma Norepinephrine via Attenuation of Brain Oxidative Stress in the DOCA-Salt Hypertensive Rats
Background. Da-Chuan-Xiong Decoction (DCXD) is an aqueous extract from a classic Chinese herbal formula composed of dried rhizomes of Ligusticum chuanxiong Hort and Gastrodia elata Bl. in the mass ratio of 4:1. It has been long used to treat chronic cardiovascular disease caused by blood stasis and wind pathogen in the clinic. This experimental study aimed to investigate the blood pressure (BP)-lowering effect of DCXD treatment on hypertension and underlying mechanisms. Methods. Male SpragueDawley rats were used in the experiment, and the hypertensive models were created by administering deoxycorticosterone acetate (DOCA) in conjunction with a high salt intake in uninephrectomized rats. DCXD was administered to hypertensive rats by oral gavage daily at a dose of 5g/kg or 2.5g/kg bodyweight for 28days. The brain sodium sensitivity, ENaC function, superoxide anion level, NADPH oxidase activity, and expression of ENaC, p67phox, p47phox, and Rac1 in the paraventricular nucleus were assessed by using the appropriate methods. Results. The 28days of DCXD (5g/kg) treatment significantly reduced the increased BP effectively, inhibited the enhanced heart index, kidney index, and 24h urinary protein, and improved the progressive pathological changes of heart and kidney, which was comparable to that of the positive control amlodipine. DCXD treatment also caused a marked reduction in plasma norepinephrine and induced a significant improvement in brain sodium sensitivity and ENaC function in DOCA-salt hypertensive rats. Rats in DCXD-treated groups also exhibited decreased superoxide anion levels and NADPH oxidase activity in the paraventricular nucleus. The level of ENaC, p67phox, and Rac1 protein expression in the paraventricular nucleus was significantly downregulated by DCXD treatment in DOCA-salt hypertensive rats. Conclusions. These findings indicate that the depressor action and sympathetic inhibition of DCXD on salt-sensitive hypertension may be by ameliorating brain sodium sensitivity, modulating ENaC function, and inhibiting the expression of ENaC and NADPH oxidase in the hypothalamic paraventricular nucleus.
- Open Access
- 23 August 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (9) , 1201
Research Progress of Flavonoids Regulating Endothelial Function
The endothelium, as the guardian of vascular homeostasis, is closely related to the occurrence and development of cardiovascular diseases (CVDs). As an early marker of the development of a series of vascular diseases, endothelial dysfunction is often accompanied by oxidative stress and inflammatory response. Natural flavonoids in fruits, vegetables, and Chinese herbal medicines have been shown to induce and regulate endothelial cells and exert anti-inflammatory, anti-oxidative stress, and anti-aging effects in a large number of in vitro models and in vivo experiments so as to achieve the prevention and improvement of cardiovascular disease. Focusing on endothelial mediation, this paper introduces the signaling pathways involved in the improvement of endothelial dysfunction by common dietary and flavonoids in traditional Chinese medicine and describes them based on their metabolism in the human body and their relationship with the intestinal flora. The aim of this paper is to demonstrate the broad pharmacological activity and target development potential of flavonoids as food supplements and drug components in regulating endothelial function and thus in the prevention and treatment of cardiovascular diseases. This paper also introduces the application of some new nanoparticle carriers in order to improve their bioavailability in the human body and play a broader role in vascular protection.
- 23 August 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (9) , 1201
Open AccessResearch Progress of Flavonoids Regulating Endothelial Function
The endothelium, as the guardian of vascular homeostasis, is closely related to the occurrence and development of cardiovascular diseases (CVDs). As an early marker of the development of a series of vascular diseases, endothelial dysfunction is often accompanied by oxidative stress and inflammatory response. Natural flavonoids in fruits, vegetables, and Chinese herbal medicines have been shown to induce and regulate endothelial cells and exert anti-inflammatory, anti-oxidative stress, and anti-aging effects in a large number of in vitro models and in vivo experiments so as to achieve the prevention and improvement of cardiovascular disease. Focusing on endothelial mediation, this paper introduces the signaling pathways involved in the improvement of endothelial dysfunction by common dietary and flavonoids in traditional Chinese medicine and describes them based on their metabolism in the human body and their relationship with the intestinal flora. The aim of this paper is to demonstrate the broad pharmacological activity and target development potential of flavonoids as food supplements and drug components in regulating endothelial function and thus in the prevention and treatment of cardiovascular diseases. This paper also introduces the application of some new nanoparticle carriers in order to improve their bioavailability in the human body and play a broader role in vascular protection.
- 23 May 2023
- Published by Springer Nature in Neurochemical Research
- Vol. 48 (9) , 2895-2910
LncRNA NKILA Exacerbates Alzheimer’s Disease Progression by Regulating the FOXA1-Mediated Transcription of TNFAIP1
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases in the world, which seriously affects AD patients’ life quality. Recently, long non-coding RNAs (lncRNAs) have been reported to play a key role in AD pathogenesis, however, the specific mechanism remains unclear. Herein, we aimed to investigate the role of lncRNA NKILA in AD. The learning and memory performance of rats from streptozotocin (STZ)-treated or other treated groups were tested by Morris water maze test. Relative levels of genes and proteins were measured using RT-qPCR and Western blotting. Mitochondrial membrane potential was tested by JC-1 staining. Levels of ROS, SOD, MDA, GSH-Px, and LDH were measured using corresponding commercial kits. Apoptosis was evaluated by TUNEL staining or Flow cytometry assay. RNA Immunoprecipitation (RIP), RNA pulldown, Chromatin immunoprecipitation (ChIP), and dual-luciferase reporter assays were utilized to test the interaction between indicated molecules. STZ treatment caused learning and memory impairment in rats and oxidative stress damage in SH-SY5Y cells. LncRNA NKILA was found to be elevated in the hippocampal tissues of rats and SH-SY5Y cells after STZ exposure. Knockdown of lncRNA NKILA alleviated STZ-induced neuronal damage. Furthermore, lncRNA NKILA could bind to ELAVL1, which regulate the stability of FOXA1 mRNA. Moreover, TNFAIP1 transcription process was controlled by FOXA1, which targeted the promoter of TNFAIP1. In vivo results demonstrated that lncRNA NKILA accelerated STZ-induced neuronal damage and oxidative stress by FOXA1/TNFAIP1 axis. Our findings indicated that knockdown of lncRNA NKILA inhibited the neuronal damage and oxidative stress induced by STZ through the FOXA1/TNFAIP1 axis, thereby alleviating the development of AD, revealing a promising therapeutic axis for AD treatment.
- 23 May 2023
- Published by Springer Nature in Neurochemical Research
- Vol. 48 (9) , 2895-2910
LncRNA NKILA Exacerbates Alzheimer’s Disease Progression by Regulating the FOXA1-Mediated Transcription of TNFAIP1
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases in the world, which seriously affects AD patients’ life quality. Recently, long non-coding RNAs (lncRNAs) have been reported to play a key role in AD pathogenesis, however, the specific mechanism remains unclear. Herein, we aimed to investigate the role of lncRNA NKILA in AD. The learning and memory performance of rats from streptozotocin (STZ)-treated or other treated groups were tested by Morris water maze test. Relative levels of genes and proteins were measured using RT-qPCR and Western blotting. Mitochondrial membrane potential was tested by JC-1 staining. Levels of ROS, SOD, MDA, GSH-Px, and LDH were measured using corresponding commercial kits. Apoptosis was evaluated by TUNEL staining or Flow cytometry assay. RNA Immunoprecipitation (RIP), RNA pulldown, Chromatin immunoprecipitation (ChIP), and dual-luciferase reporter assays were utilized to test the interaction between indicated molecules. STZ treatment caused learning and memory impairment in rats and oxidative stress damage in SH-SY5Y cells. LncRNA NKILA was found to be elevated in the hippocampal tissues of rats and SH-SY5Y cells after STZ exposure. Knockdown of lncRNA NKILA alleviated STZ-induced neuronal damage. Furthermore, lncRNA NKILA could bind to ELAVL1, which regulate the stability of FOXA1 mRNA. Moreover, TNFAIP1 transcription process was controlled by FOXA1, which targeted the promoter of TNFAIP1. In vivo results demonstrated that lncRNA NKILA accelerated STZ-induced neuronal damage and oxidative stress by FOXA1/TNFAIP1 axis. Our findings indicated that knockdown of lncRNA NKILA inhibited the neuronal damage and oxidative stress induced by STZ through the FOXA1/TNFAIP1 axis, thereby alleviating the development of AD, revealing a promising therapeutic axis for AD treatment.
- Open Access
- 18 January 2022
- Published by Wiley in International Journal of Hypertension
- Vol. 2022, 1-11
Involvement of Neuropeptide Y within Paraventricular Nucleus in Electroacupuncture Inhibiting Sympathetic Activities in Hypertensive Rats
Although electroacupuncture (EA) has been used to decrease the blood pressure (BP) clinically, the underlying mechanisms are not clearly clarified. This study aimed to assess the hypothesis that EA treatment exerts a hypotensive action via suppressing sympathetic activities and modulating neuropeptide Y (NPY) function within the paraventricular nucleus (PVN) of hypertensive rats. Male Sprague-Dawley rats were selected for the experiment, and the hypertensive models were established by the two-kidney, one-clip (2K1C) method. Then, the rats were randomly assigned to the sham group, 2K1C group, 2K1C plus EA group, and 2K1C plus sham EA group. EA treatment at the acupoints ST36 and ST40 overlying the peroneal nerves was given once a day for 30 days. The radiotelemetry system was applied to collect the arterial BP recordings. Power spectral analyses of BP variability, BP responses to ganglionic blockade, and plasma levels of norepinephrine and epinephrine were performed to assess the changes in sympathetic nerve activity. Real-time PCR and Western blots were carried out to examine the expression of NPY system in the PVN. The responses of PVN microinjection with NPY Y1R antagonist BIBO3304 were detected to check the endogenous NPY tone. The results showed that the enhanced arterial BP and sympathetic activities were effectively reduced by 30 days of EA treatment, and baroreflex sensitivity was improved in 2K1C hypertensive rats. The level of NPY mRNA and protein expression in the PVN was markedly upregulated by EA treatment in 2K1C rats. In addition, the pressor responses of PVN microinjection with NPY Y1R antagonist BIBO3304 in 2K1C models were remarkably augmented by the EA stimulation. Our results indicate that the increased NPY expression and function in the PVN induced by EA treatment contribute to antihypertensive and sympathetic suppression on hypertensive rats. The findings may elucidate the underlying mechanisms of the acupuncture to be a potential therapeutic strategy against hypertension.
- 18 January 2022
- Published by Wiley in International Journal of Hypertension
- Vol. 2022, 1-11
Open AccessInvolvement of Neuropeptide Y within Paraventricular Nucleus in Electroacupuncture Inhibiting Sympathetic Activities in Hypertensive Rats
Although electroacupuncture (EA) has been used to decrease the blood pressure (BP) clinically, the underlying mechanisms are not clearly clarified. This study aimed to assess the hypothesis that EA treatment exerts a hypotensive action via suppressing sympathetic activities and modulating neuropeptide Y (NPY) function within the paraventricular nucleus (PVN) of hypertensive rats. Male Sprague-Dawley rats were selected for the experiment, and the hypertensive models were established by the two-kidney, one-clip (2K1C) method. Then, the rats were randomly assigned to the sham group, 2K1C group, 2K1C plus EA group, and 2K1C plus sham EA group. EA treatment at the acupoints ST36 and ST40 overlying the peroneal nerves was given once a day for 30 days. The radiotelemetry system was applied to collect the arterial BP recordings. Power spectral analyses of BP variability, BP responses to ganglionic blockade, and plasma levels of norepinephrine and epinephrine were performed to assess the changes in sympathetic nerve activity. Real-time PCR and Western blots were carried out to examine the expression of NPY system in the PVN. The responses of PVN microinjection with NPY Y1R antagonist BIBO3304 were detected to check the endogenous NPY tone. The results showed that the enhanced arterial BP and sympathetic activities were effectively reduced by 30 days of EA treatment, and baroreflex sensitivity was improved in 2K1C hypertensive rats. The level of NPY mRNA and protein expression in the PVN was markedly upregulated by EA treatment in 2K1C rats. In addition, the pressor responses of PVN microinjection with NPY Y1R antagonist BIBO3304 in 2K1C models were remarkably augmented by the EA stimulation. Our results indicate that the increased NPY expression and function in the PVN induced by EA treatment contribute to antihypertensive and sympathetic suppression on hypertensive rats. The findings may elucidate the underlying mechanisms of the acupuncture to be a potential therapeutic strategy against hypertension.